Literature DB >> 9821109

An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro.

N Sugawa1, S Ueda, Y Nakagawa, H Nishino, K Nosaka, A Iwashima, M Kurimoto.   

Abstract

Epidermal growth factor receptor (EGFR) plays an important role in the progression of malignancy in gliomas. We studied the growth inhibition of the malignant glioma cell lines using an antisense EGFR oligodeoxynucleotide enveloped with Lipofectin. At a concentration of 5 microM of the antisense EGFR oligodeoxynucleotide enveloped with Lipofectin, the proliferation of three malignant glioma cell lines was significantly inhibited (p < 0.05) compared with that of the cells exposed to 5 microM sense EGFR oligodeoxynucleotide. The activity of the tyrosine kinase and the DNA synthesis was also significantly suppressed (p < 0.05). These findings show that the antisense EGFR oligodeoxynucleotide enveloped with Lipofectin has a possibility to become a useful gene therapy against malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9821109     DOI: 10.1023/a:1005903002865

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

Review 1.  Epidermal growth factor, its receptor, and related proteins.

Authors:  G Carpenter; J G Zendegui
Journal:  Exp Cell Res       Date:  1986-05       Impact factor: 3.905

2.  Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails.

Authors:  A J Ekstrand; N Sugawa; C D James; V P Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

3.  mRNA phenotyping by enzymatic amplification of randomly primed cDNA.

Authors:  K E Noonan; I B Roninson
Journal:  Nucleic Acids Res       Date:  1988-11-11       Impact factor: 16.971

4.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

5.  Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma.

Authors:  R J Packer; L N Sutton; J W Goldwein; G Perilongo; G Bunin; J Ryan; B H Cohen; G D'Angio; E D Kramer; R A Zimmerman
Journal:  J Neurosurg       Date:  1991-03       Impact factor: 5.115

6.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.

Authors:  M D Walker; E Alexander; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; H A Norrell; G Owens; J Ransohoff; C B Wilson; E A Gehan; T A Strike
Journal:  J Neurosurg       Date:  1978-09       Impact factor: 5.115

7.  Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines.

Authors:  Y H Xu; N Richert; S Ito; G T Merlino; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

8.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.

Authors:  R Nishikawa; X D Ji; R C Harmon; C S Lazar; G N Gill; W K Cavenee; H J Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

9.  Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.

Authors:  D E Neal; C Marsh; M K Bennett; P D Abel; R R Hall; J R Sainsbury; A L Harris
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

10.  erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.

Authors:  R Colomer; R Lupu; S S Bacus; E P Gelmann
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more
  6 in total

Review 1.  Molecular therapy in ocular wound healing.

Authors:  M F Cordeiro; G S Schultz; R R Ali; S S Bhattacharya; P T Khaw
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

Review 2.  Getting into the brain: approaches to enhance brain drug delivery.

Authors:  Mayur M Patel; Bhoomika R Goyal; Shraddha V Bhadada; Jay S Bhatt; Avani F Amin
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

3.  Protein delivery of caspase-3 induces cell death in malignant C6 glioma, primary astrocytes and immortalized and primary brain capillary endothelial cells.

Authors:  Birgit Zassler; Ingolf E Blasig; Christian Humpel
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 4.  Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma.

Authors:  Jun Yoshida; Masaaki Mizuno
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

Review 5.  Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.

Authors:  Lee A Selznick; Mohammed F Shamji; Peter Fecci; Matthias Gromeier; Allan H Friedman; John Sampson
Journal:  Neurosurg Rev       Date:  2008-02-08       Impact factor: 3.042

Review 6.  Nanocarriers Call the Last Shot in the Treatment of Brain Cancers.

Authors:  Amin Mehrabian; Mohammad Mashreghi; Saba Dadpour; Ali Badiee; Leila Arabi; Seyedeh Hoda Alavizadeh; Seyedeh Alia Moosavian; Mahmoud Reza Jaafari
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.